{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:08:24Z","timestamp":1785276504942,"version":"3.55.0"},"reference-count":26,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,5,24]],"date-time":"2018-05-24T00:00:00Z","timestamp":1527120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["JGH Open"],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec><jats:title>Background and Aim<\/jats:title><jats:p>Drug\u2010induced autoimmune hepatitis (DIAIH) is an adverse effect associated with several drugs that usually occurs acutely, with variable latency, and it may potentially be mortal. There are a few reports and studies about DIAIH.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was an analytical study of a retrospective cohort of patients, discriminated according to idiopathic or drug\u2010induced etiology, followed up for a 7\u2010year period until 31 December 2016.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 190 patients were selected for the analysis, 12 (6.3%) with DIAIH. The two main drugs related to DIAIH were nitrofurantoin, <jats:italic>n<\/jats:italic>\u2009=\u20098 (67%), and NSAID, <jats:italic>n<\/jats:italic>\u2009=\u20092 (17%), constituting 84% of the cases. There were no significant differences in seropositivity between AIH with DIAIH in antinuclear antibodies (ANA) and anti\u2010smooth muscle antibodies (ASMA) antibodies, with 82.6% <jats:italic>versus<\/jats:italic> 82.6% and 34% <jats:italic>versus<\/jats:italic> 16%, respectively. The fibrosis stages were similar, except for the F4 stage, in a greater proportion in AIH. None of the patients with DIAIH had cirrhosis or developed it during follow\u2010up, but it was present in 42.1% of the AIH cases at diagnosis (<jats:italic>P<\/jats:italic>\u2009=\u20090.003). Biochemical remission with management was higher in DIAIH but not significant (91.7% <jats:italic>vs<\/jats:italic> 80.9%, <jats:italic>P<\/jats:italic>\u2009=\u20090.35). The definitive interruption of immunosuppression was successfully performed in 25% of those with DIAIH without relapses but was only possible in 2.8% in AIH (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001) with 32 cases of relapses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>DIAIH constitutes a minor proportion of AIH. The clinical and histological characteristics may be similar; DIAIH patients have a greater chance of having treatment suspended with a low risk of relapse, progression to cirrhosis, or need for liver transplant.<\/jats:p><\/jats:sec>","DOI":"10.1002\/jgh3.12054","type":"journal-article","created":{"date-parts":[[2018,5,25]],"date-time":"2018-05-25T06:05:23Z","timestamp":1527228323000},"page":"97-104","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Differential characteristics in drug\u2010induced autoimmune hepatitis"],"prefix":"10.1002","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2609-1233","authenticated-orcid":false,"given":"Omar Yesid","family":"Mart\u00ednez\u2010Casas","sequence":"first","affiliation":[{"name":"Clinical Hepatology Universidad de Antioquia  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Sebasti\u00e1n","family":"D\u00edaz\u2010Ram\u00edrez","sequence":"additional","affiliation":[{"name":"Clinical Hepatology Universidad de Antioquia  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Ignacio","family":"Mar\u00edn\u2010Zuluaga","sequence":"additional","affiliation":[{"name":"Gastrohepatology Group Universidad de Antioquia  Medell\u00edn Colombia"},{"name":"Hepatology Unit and Hepatic Transplant Pablo Tob\u00f3n Uribe Hospital  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Octavio","family":"Mu\u00f1oz\u2010Maya","sequence":"additional","affiliation":[{"name":"Gastrohepatology Group Universidad de Antioquia  Medell\u00edn Colombia"},{"name":"Hepatology Unit and Hepatic Transplant Pablo Tob\u00f3n Uribe Hospital  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4449-7499","authenticated-orcid":false,"given":"Oscar","family":"Santos","sequence":"additional","affiliation":[{"name":"Gastrohepatology Group Universidad de Antioquia  Medell\u00edn Colombia"},{"name":"Hepatology Unit and Hepatic Transplant Pablo Tob\u00f3n Uribe Hospital  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Hernando","family":"Donado\u2010G\u00f3mez","sequence":"additional","affiliation":[{"name":"Gastrohepatology Group Universidad de Antioquia  Medell\u00edn Colombia"},{"name":"Epidemiology Unit Pablo Tob\u00f3n Uribe Hospital  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Restrepo\u2010Guti\u00e9rrez","sequence":"additional","affiliation":[{"name":"Gastrohepatology Group Universidad de Antioquia  Medell\u00edn Colombia"},{"name":"Hepatology Unit and Hepatic Transplant Pablo Tob\u00f3n Uribe Hospital  Medell\u00edn Colombia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,24]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1089-3261(02)00025-9"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1155\/2000\/910107"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24481"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-015-1131-7"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.02.024"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v6.i4.160"},{"key":"e_1_2_5_8_1","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1002\/hep.23588","article-title":"Drug\u2010induced autoimmune hepatitis: clinical characteristics and prognosis","volume":"51","author":"E1 B","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_5_9_1","first-page":"A271","article-title":"Drug\u2010induced autoimmune hepatitis: a frequent disorder","volume":"56","author":"Heurgu\u00e9 A","year":"2007","journal-title":"Gut"},{"key":"e_1_2_5_10_1","first-page":"147","article-title":"Hepatitis autoinmune asociada al uso de adalimumab en un paciente con artritis reumatoide","volume":"37","author":"Aristiz\u00e1bal N","year":"2012","journal-title":"Acta M\u00e9dica Colomb."},{"key":"e_1_2_5_11_1","first-page":"86","article-title":"Autoimmune hepatitis induced by isotretionine","volume":"36","author":"Guzman Rojas P","year":"2016","journal-title":"Rev Gastroenterol Per\u00fa"},{"key":"e_1_2_5_12_1","article-title":"Characterization of patients with autoimmune hepatitis at an university hospital in Medell\u00edn\u2010Colombia: cohort study","volume":"41","author":"D\u00edaz\u2010Ram\u00edrez GS","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"e_1_2_5_13_1","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.23696","article-title":"Standardization of nomenclature and causality assessment in drug\u2010induced liver injury: summary of a clinical research workshop","volume":"52","author":"Day P","year":"2010","journal-title":"Hepatology"},{"key":"e_1_2_5_14_1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Dalekos GN","year":"2008","journal-title":"Hepatology"},{"key":"e_1_2_5_15_1","first-page":"20","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"Centre C","year":"2007","journal-title":"BMJ"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.08.040"},{"key":"e_1_2_5_17_1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2016.05.043","article-title":"Features of autoimmune hepatitis in patients with drug\u2010induced liver injury","volume":"15","author":"Boer YS","year":"2016","journal-title":"Clin. Gastroenterol Hepatol."},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0805-5"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01316809"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v21.i24.7584"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.05.027"},{"key":"e_1_2_5_22_1","first-page":"172","article-title":"Propylthiouracil\u2010induced overt hepatic injury in patients with hyperthyroidism","volume":"26","author":"Lian XL","year":"2004","journal-title":"Zhongguo Yi Xue Ke Xue Yuan Xue Bao"},{"key":"e_1_2_5_23_1","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2169\/internalmedicine.42.331","article-title":"Autoimmune hepatitis associated with Graves\u2019 disease","volume":"42","author":"Cui B","year":"2003","journal-title":"Intern. Med."},{"key":"e_1_2_5_24_1","first-page":"205","article-title":"A case of autoimmune hepatitis with Graves\u2019 disease treated by propylthiouracil","volume":"73","author":"Sato I","year":"2011","journal-title":"Nagoya J. Med. Sci."},{"key":"e_1_2_5_25_1","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1399-3046.2006.00487.x","article-title":"Propylthiouracil\u2010associated liver failure presenting as probable autoimmune hepatitis in a child with Graves\u2019 disease","volume":"10","author":"Web S","year":"2006","journal-title":"Pediatr. Transplant."},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3603"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000480139"}],"container-title":["JGH Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjgh3.12054","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jgh3.12054","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T22:34:25Z","timestamp":1695508465000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jgh3.12054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,24]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["10.1002\/jgh3.12054"],"URL":"https:\/\/doi.org\/10.1002\/jgh3.12054","archive":["Portico"],"relation":{},"ISSN":["2397-9070","2397-9070"],"issn-type":[{"value":"2397-9070","type":"print"},{"value":"2397-9070","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,24]]},"assertion":[{"value":"2017-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}